These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23624215)

  • 1. Immunomodulatory effects of silymarin in patients with β-thalassemia major.
    Gharagozloo M; Karimi M; Amirghofran Z
    Int Immunopharmacol; 2013 Jun; 16(2):243-7. PubMed ID: 23624215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients.
    Alidoost F; Gharagozloo M; Bagherpour B; Jafarian A; Sajjadi SE; Hourfar H; Moayedi B
    Int Immunopharmacol; 2006 Aug; 6(8):1305-10. PubMed ID: 16782543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
    Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M
    Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of TGFβ, IL-10, IL-17, and IL-23 cytokines in β-thalassemia major patients: the impact of silymarin therapy.
    Balouchi S; Gharagozloo M; Esmaeil N; Mirmoghtadaei M; Moayedi B
    Immunopharmacol Immunotoxicol; 2014 Aug; 36(4):271-4. PubMed ID: 24945737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-faced cell-mediated immunity in beta-thalassemia major: stimulated phenotype versus suppressed activity.
    Gharagozloo M; Karimi M; Amirghofran Z
    Ann Hematol; 2009 Jan; 88(1):21-7. PubMed ID: 18690440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of iron loading and iron chelation on the proliferation and telomerase activity of human peripheral blood mononuclear cells.
    Bagherpour B; Gharagozloo M; Moayedi B
    Iran J Immunol; 2009 Mar; 6(1):33-9. PubMed ID: 19293476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.
    Zareifar S; Jabbari A; Cohan N; Haghpanah S
    Arch Iran Med; 2009 Sep; 12(5):488-91. PubMed ID: 19722772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Pagano L; Prossomariti L
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: therapeutic implications for autoimmune diseases.
    Gharagozloo M; Javid EN; Rezaei A; Mousavizadeh K
    Basic Clin Pharmacol Toxicol; 2013 Apr; 112(4):251-6. PubMed ID: 23121838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
    Aydinok Y; Ulger Z; Nart D; Terzi A; Cetiner N; Ellis G; Zimmermann A; Manz C
    Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Origa R; Bina P; Agus A; Crobu G; Defraia E; Dessì C; Leoni G; Muroni PP; Galanello R
    Haematologica; 2005 Oct; 90(10):1309-14. PubMed ID: 16219566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of silymarin on antioxidant and oxidative status in patients with β-thalassemia major: A crossover, randomized controlled trial.
    Darvishi-Khezri H; Salehifar E; Kosaryan M; Karami H; Alipour A; Shaki F; Aliasgharian A
    Complement Ther Med; 2017 Dec; 35():25-32. PubMed ID: 29154063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
    Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D; Giardini C; Angelucci E; Polchi P; Galimberti M; Baronciani D; Erer B; Maiello A; Lucarelli G
    Haematologica; 1995; 80(4):300-4. PubMed ID: 7590497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
    Shamsian BS; Aminasnafi A; Moghadassian H; Gachkar L; Arzanian MT; Alavi S; Esfehani H; Garallahi F; Amini R
    Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coadministration of silymarin with iron chelators in transfusion-dependent β-thalassemia patients: a systematic review and meta-analysis for effect on iron overload.
    Darvishi-Khezri H; Naderisorki M; Zahedi M; Mortazavi P; Tajik F; Nasirzadeh A; Karami H
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1445-1453. PubMed ID: 34486906
    [No Abstract]   [Full Text] [Related]  

  • 20. The Effects and Safety of Silymarin on β-thalassemia in Children and Adolescents: A Systematic Review based on Clinical Trial Studies.
    Rahimi-Dehkordi N; Heidari-Soureshjani S; Sherwin CMT
    Rev Recent Clin Trials; 2024; 19(4):242-255. PubMed ID: 38818907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.